In order to facilitate the performance of pharmacovigilance activities within the Union, the Agency shall, in cooperation with competent authorities and other interested parties, draw up:

1. (a)

   guidance on good pharmacovigilance practices for both competent authorities and marketing authorisation holders;

2. (b)

   scientific guidance on post-authorisation efficacy studies.